| Literature DB >> 28702222 |
Carlos André Minanni1, Ana Luiza De Almeida Cardoso1, Edoarda Vasco de Albuquerque Albuquerque1, Luciana Pinto Brito2, Ludmilla Malveira Lima Lopes1, Andrea Glezer1, Elisa Del Rosario Ugarte Verduguez3, Berenice Bilharinho De Mendonça2, Marcello Delano Bronstein1, Marcio Carlos Machado1, Maria Candida Barisson Villares Fragoso1,4.
Abstract
Münchhausen's syndrome (MS) is a chronic factitious disorder characterized by the intentional production of clinical symptoms without external incentive. One type of MS is factitious Cushing syndrome, an extremely rare clinical situation in which the diagnosis is challenging mainly due to interference of the exogenous medication in cortisol immunoassays. We described a 26-year-old woman who was originally diagnosed with a macroprolactinoma and during follow-up developed clinical and laboratorial hypercortisolism. A transsphenoidal surgery was performed and immunohistochemistry revealed positive and diffuse staining for both hormones. Four years later, her hypercortisolism recurred and the confirmation of factitious Cushing syndrome was delayed due to conflicting laboratorial results. There are few cases in the literature of factitious Cushing syndrome, and only one had a fatal outcome. The diagnosis of this condition is complex and includes cyclic Cushing syndrome in the differential diagnosis. These patients have high morbidity and increased mortality risk and are likely to have other psychiatric disorders. Prednisone was identified as the culprit in the majority of the cases.Entities:
Keywords: Cortisol immunoassay; Factitious Cushing’s syndrome; Münchhausen’s syndrome
Year: 2015 PMID: 28702222 PMCID: PMC5469202 DOI: 10.1186/s40842-015-0002-8
Source DB: PubMed Journal: Clin Diabetes Endocrinol ISSN: 2055-8260
Hormonal profile during the follow-up
| Exam | Mar/2006 | Jan/2010 | Aug/2013 | Normal range |
|---|---|---|---|---|
| Before TS* | After TS** | Recurrence | ||
| ACTH | 43 | 27 | 24 | <46 pg/mL |
| Salivary cortisol (midnight) | 0.13 | <0.1 | 2.49 | <0.12 μg/dL |
| Overnight DST§ | 4.1 | NA | 15.1 | <1.8 μg/dL |
| 24-h UTC | NA | 132 | 12,200 | 50 - 310 μg/24 h |
| Serum cortisol (morning) | 19.6 | 11.4 | 33 | 5 - 25 μg/dL |
| DHEA-S | 2,246 | NA | 208 | 988 – 3,400 ng/mL |
| LH | 1.1 | 0.2 | 0.9 | 14.0 – 95.6 IU/L |
| FSH | 1.7 | <1 | 2.4 | 4.7 – 21.5 IU/L |
| E2 | 42.6 | <13 | <15 | 85.8 – 498.0 pg/mL |
| Prolactin | 57 | 13.3 | 27 | 4.8 – 23.3 ng/mL |
| TSH | <0.03 | <0.03 | 0.58 | 0.27 – 4.20 μIU/mL |
| Free T4 | 1.2 | 0.97 | 0.63 | 0.93 - 1.70 ng/dL |
| GH | 0.6 | <0.1 | <0.1 | <4.4 ng/mL |
| IGF-I | 179 | 75 | 26 | 152.7 – 396.5 ng/mL |
*Using bromocriptine 5 mg/day, **Using cabergoline 0.5 mg/day, TS: transsphenoidal surgery, §Dexamethasone suppression test
Biochemical findings during hospitalization
| Exam | Aug/2013 | Normal range |
|---|---|---|
| Sodium | 140 | 135 - 145 mEq/L |
| Potassium | 4.4 | 3.5 – 5.0 mEq/L |
| Calcium | 9.1 | 8.60 – 10.20 mg/dL |
| PTH | 41 | 15 - 65 pg/mL |
| 25OH vitamin D | 18 | 30 - 100 ng/mL |
| Urea | 25 | 10 - 50 mg/dL |
| Creatinine | 0.61 | 0.50 – 0.90 mg/dL |
| HbA1C | 7.2 | 4.1 – 6 % |
| Glucose | 130 | 70 - 100 mg/dL |
| HDL-cholesterol | 51 | <65 mg/dL |
| LDL-cholesterol | 129 | <130 mg/dL |
| Cholesterol | 342 | <200 mg/dL |
| Triglycerides | 1,514 | <150 mg/dL |
Fig. 1Evolution of UTC, salivary F and serum F during follow-up, normalized by the upper limit normal range (ULNR)
Fig. 2MRI sequences during follow-up. (A) May/2007: coronal view on T 1-weighted MRI of the pituitary gland identified a heterogeneous solid macroadenoma (1.9x1.8 cm of diameter – arrow). (B) August/2013: MRI after four years of transsphenoidal surgery – questionable remnant tumor tissue or arachnoid cyst (arrow)
Clinical and laboratorial data from 22 patients with factitious Cushing’s syndrome from review of literature
| Authors | Age (year) | Gender | 24 h UC | DST | Serum cortisol | Plasma ACTH | Pituitary MRI | Adrenal CT | Medication |
|---|---|---|---|---|---|---|---|---|---|
| Witt, 1981 [ | 15 | F | Up | Suppression | Up | N | Normal | Normal | Prednisone |
| Cook, 1985 [ | 33 | F | Lo | Absent | Up | N | Normal | NA | NA |
| O’Hare, 1986 [ | 22 | M | Up | Suppression | V | N | Normal | Normal | Hydrocortisone |
| Anderson, 1993 [ | 46 | F | N | NA | Lo | NA | Normal | Normal | Prednisolone |
| Anderson, 1993 [ | 23 | F | Lo | NA | N | NA | NA | Normal | Prednisone |
| O’Shaughnessy, 1995 [ | 37 | F | Up | Suppression | Up | N | Questionable | Normal | Prednisolone |
| Workman, 1995 [ | 33 | F | Up | Suppression | N | N | NA | NA | Hydrocortisone |
| Cizza, 1996 [ | 37 | F | V | Paradoxical | Up | Up | Microadenoma | Normal | Prednisolone/Dexamethasone |
| Cizza, 1996 [ | 31 | M | Up | Absent | Up | Lo | Microadenoma | Atrophy | Cortisone |
| Cizza, 1996 [ | 44 | F | Up | NA | N | N | Questionable | Normal | Unknown |
| Cizza, 1996 [ | 32 | F | V | Suppression | Lo | NA | Questionable | Atrophy | Unknown |
| Cizza, 1996 [ | 36 | F | NA | NA | Lo | Lo | Normal | Left-sided mass | Prednisolone |
| Cizza, 1996 [ | 31 | F | Lo | NA | Lo | Lo | Normal | Atrophy | Prednisone |
| Villanueva, 2000 [ | 37 | F | Lo | NA | Lo | NA | NA | NA | Dexamethasone |
| Villanueva, 2000 [ | 57 | F | V | NA | V | Lo | Normal | Normal | Dexamethasone |
| Villanueva, 2000 [ | 47 | F | NA | NA | V | Lo | Normal | Right-sided mass | Unknown |
| Villanueva, 2000 [ | 54 | F | Lo | NA | Lo | Lo | Normal | NA | Dexamethasone |
| Ach, 2005 [ | 29 | M | N | NA | N | N | NA | Normal | Dexamethasone/Hydrocortisone |
| Ach, 2005 [ | 60 | M | N | NA | N | NA | NA | NA | Betamethasone |
| Kansagara, 2006* [ | 33 | F | Lo | NA | Lo | N | Normal | Normal | Prednisone |
| Thynne, 2013 [ | 54 | F | Up | NA | V | V | Normal | Normal | Prednisolone |
NA: not available; Up: upper; Lo: lower; N: normal; V: variable F (female), M(male), DST (dexamethasone suppression test), UC urinary cortisol *Fatal case